4//SEC Filing
Grygiel Nancy A. 4
Accession 0000318154-25-000083
CIK 0000318154other
Filed
Nov 20, 7:00 PM ET
Accepted
Nov 21, 8:34 PM ET
Size
14.6 KB
Accession
0000318154-25-000083
Insider Transaction Report
Form 4
AMGEN INCAMGN
Grygiel Nancy A.
SVP & CCO
Transactions
- Exercise/Conversion
Nqso (Right to Buy)
2025-11-20−1,639→ 0 totalExercise: $162.60From: 2019-05-01Exp: 2027-05-01→ Common Stock (1,639 underlying) - Exercise/Conversion
Common Stock
2025-11-20$177.46/sh+1,500$266,190→ 8,725 total - Sale
Common Stock
2025-11-20$337.26/sh−1,639$552,773→ 7,225 total - Exercise/Conversion
Nqso (Right to Buy)
2025-11-20−1,500→ 1,970 totalExercise: $177.46From: 2020-04-27Exp: 2028-04-27→ Common Stock (1,500 underlying) - Sale
Common Stock
2025-11-20$337.26/sh−1,500$505,894→ 7,225 total - Exercise/Conversion
Common Stock
2025-11-20$162.60/sh+1,639$266,501→ 8,864 total
Holdings
- 104.685(indirect: By 401(k))
Common Stock
Footnotes (3)
- [F1]The price reported is an average price. The prices ranged from $337.17 to $337.69 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer.
- [F2]These shares include 96 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
- [F3]These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.
Documents
Issuer
AMGEN INC
CIK 0000318154
Entity typeother
Related Parties
1- filerCIK 0001816414
Filing Metadata
- Form type
- 4
- Filed
- Nov 20, 7:00 PM ET
- Accepted
- Nov 21, 8:34 PM ET
- Size
- 14.6 KB